Clozapine and COVID-19
- PMID: 32584527
- PMCID: PMC7828924
- DOI: 10.1503/jpn.2045301
Clozapine and COVID-19
Conflict of interest statement
G. Remington has received clinical, research and advisory board support from HLS Therapeutics, consultant fees from Mitsubishi-Tanabe Pharma Corporation, and research support from the University of Toronto, Canadian Institutes of Health Research (CIHR) and Research Hospital Fund–Canada Foundation for Innovation (RHF-CFI). No other competing interests were declared.
Comment in
-
Clozapine and COVID-19: The authors respond.J Psychiatry Neurosci. 2020 Jul 1;45(4):E1-E2. doi: 10.1503/jpn.2045302. J Psychiatry Neurosci. 2020. PMID: 32584530 Free PMC article. No abstract available.
Comment on
- J Psychiatry Neurosci. 2020 Apr 03;45(4):200061.
-
Consensus statement on the use of clozapine during the COVID-19 pandemic.J Psychiatry Neurosci. 2020 May 1;45(3):222-223. doi: 10.1503/jpn.200061. Epub 2020 Apr 3. J Psychiatry Neurosci. 2020. PMID: 32297722 Free PMC article. No abstract available.
References
-
- Myles N, Myles H, Xia S, et al. Meta-analysis examining the epidemiology of clozapine-associated neutropenia. Acta Psychiatr Scand. 2018;138:101–9. - PubMed
-
- Whiskey E, Dzahini O, Ramsay R, et al. Need to bleed? Clozapine haematological monitoring approaches a time for change. Int Clin Psychopharmacol. 2019;34:264–8. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources